MGI PHARMA SALAGEN MARKETING SET TO BEGIN BY EARLY MAY
Executive Summary
MGI PHARMA SALAGEN MARKETING SET TO BEGIN BY EARLY MAY for treatment of radiation-induced chronic dry mouth (xerostomia) in head and neck cancer patients following the March 22 approval of the oral pilocarpine compound. Salagen, an orphan drug, has been given a "3P" rating by FDA, designating a new formulation of an already approved drug given a priority review at the agency. Pilocarpine in an ophthalmic formulation is used to treat glaucoma.